• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Braeburn Pharmaceuticals

Titan, Braeburn end commercialization deal for Probuphine drug-delivery implant

May 30, 2018 By Sarah Faulkner

Titan Pharmaceuticals (NSDQ:TTNP) and Braeburn Pharmaceuticals said today that they plan to end a 2012 licensing agreement that gave Braeburn exclusive rights to commercialize Probuphine in the U.S. and Canada. Probuphine, which was developed using Titan’s ProNeura continuous drug-delivery tech, is an implant that can be placed in a patient’s upper arm in an outpatient office […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, Titan Pharmaceuticals

Braeburn dealt setback over monthly, weekly opioid abuse therapy

January 22, 2018 By Sarah Faulkner

The FDA has issued a complete response letter to Braeburn Pharmaceuticals, denying its application for an investigational weekly and monthly buprenorphine depot injection designed to treat adults with opioid use disorder. The company reported that the dreaded CRL does not request additional clinical studies, but Braeburn did not elaborate as to what sort of additional information […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pain Management, Pharmaceutical, Regulatory/Compliance Tagged With: Braeburn Pharmaceuticals

Braeburn raises $110m for opioid use disorder depot injection

January 11, 2018 By Sarah Faulkner

Braeburn Pharmaceuticals has raised $110 million in a mezzanine round of financing led by Wellington Capital. Other investors included Avista Capital Partners, RA Capital Management, Deerfield Management and Apple Tree Partners. The Princeton, N.J.-based company said it plans to use the new funds to support the FDA approval process and commercialization of CAM2038, a weekly and […]

Filed Under: Drug-Device Combinations, Funding Roundup, Pain Management, Pharmaceutical Tagged With: Braeburn Pharmaceuticals

Braeburn, Camurus seek FDA nod for buprenorphine depot

July 20, 2017 By Sarah Faulkner

Camurus AB (STO:CAMX) and Braeburn Pharmaceuticals said today that the companies submitted a new drug application to the FDA for its weekly and monthly buprenorphine depots to treat opioid use disorder. Braeburn also reported that it applied for priority review of its application, which could potentially shorten the company’s path to the market. Get the full story at […]

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Pain Management, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, camurus

Camarus, Braeburn tout Phase II data for long-acting buprenorphine depot

June 23, 2017 By Sarah Faulkner

Camarus AB (STO:CAMX) and Braeburn Pharmaceuticals touted data yesterday from a Phase II trial of its long-acting buprenorphine depot. The 47-patient trial found that CAM2038 blocks the effects of opioids and suppresses withdrawal symptoms in adults with opioid use disorder. The in-patient trial included 5 3-day test sessions to evaluate the patients’ response to randomized […]

Filed Under: Clinical Trials, Pain Management, Pharmaceutical, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, Camarus AB

Braeburn names former Teva exec as new president, CEO | Personnel Moves – June 14, 2017

June 14, 2017 By Sarah Faulkner

Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. Most recently, Derkacz worked as senior VP and head of global central nervous system and pain therapeutic areas for Teva Pharmaceuticals (NYSE:TEVA). Behshad Sheldon, who helped to found Braeburn in 2012, is slated to step down from Braeburn […]

Filed Under: Blog Tagged With: alexionpharmaceuticals, AstraZeneca plc, Biogen, Braeburn Pharmaceuticals, cytrx, Dicerna Pharmaceuticals, Merrimack Pharmaceuticals, Novartis, oculartherapeutix, Sanofi-Aventis, uniqure

Braeburn, Knight seek Health Canada nod for opioid dependence implant

June 13, 2017 By Sarah Faulkner

Braeburn Pharmaceuticals and Knight Therapeutics (TSE:GUD) said today that Health Canada has agreed to review Knight’s new drug submission for Probuphine, a buprenorphine subdermal implant designed to treat opioid drug dependence. In February last year, Braeburn and Knight inked an exclusive distribution and sublicense deal, giving Knight the exclusive right to distribute Probuphine in Canada. Get […]

Filed Under: Drug-Device Combinations, Implants, Pain Management, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, Knight Therapeutics

Braeburn, Camurus tout long-term phase III data for opioid addiction therapy

May 2, 2017 By Sarah Faulkner

Braeburn Pharmaceuticals and Camurus (STO:CAMX) touted data today from a long-term Phase III study of its weekly and monthly buprenorphine depots in patients with moderate-to-severe opioid use disorder. The safety and efficacy study enrolled 228 patients and 71% of participants completed the 48-week treatment. The safety profile of CAM2038 was comparable to previous, shorter studies, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, camurus

Braeburn’s risperidone implant meets primary endpoint in schizophrenia trial

April 27, 2017 By Sarah Faulkner

Braeburn Pharmaceuticals said yesterday that a 6-month study of its risperidone implant in patients with schizophrenia or schizoaffective disorder met its primary endpoint. Risperidone, the most commonly-prescribed therapy for schizophrenia, depends on consistent administration, but patients with schizophrenia sometimes stop taking their medication when their symptoms improve. Long-acting, injectable formulations of risperidone are on the market, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Neurological, Pharmaceutical, Wall Street Beat Tagged With: Braeburn Pharmaceuticals

Opioid treatment implant-maker Braeburn secretly funded advocacy group fronted by Gingrich

March 7, 2017 By Sarah Faulkner

Opioid treatment implant-maker Braeburn Pharmaceuticals said in a regulatory filing last month that it has made charitable donations to an advocacy group fronted by Newt Gingrich and Patrick Kennedy known as Advocates for Opioid Recovery. The group lobbies for more government funding and insurance coverage for opioid maintenance treatments. Former Republican House speaker Gingrich and former […]

Filed Under: Drug-Device Combinations, Legal News, Pharmaceutical, Wall Street Beat Tagged With: Braeburn Pharmaceuticals

Braeburn pulls the plug on $150m IPO, citing market conditions

February 3, 2017 By Sarah Faulkner

Braeburn Pharmaceuticals pulled its plans for a $150 million initial public offering yesterday, citing unstable market conditions. The Princeton, N.J.-based company 1st announced plans to go public in late December and in mid-January, Braeburn said it planned to raise $150 million by offering 7,692,308 shares of its common stock at $18.00 to $21.00 apiece. The company […]

Filed Under: Drug-Device Combinations, Initial Public Offering (IPO), Wall Street Beat Tagged With: Braeburn Pharmaceuticals

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS